A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

Completed · Phase 1

Conditions studied: Healthy

In brief

Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine. The goals of the trial are to learn: * What happens to different forms of MK-1167 in a healthy person's body over time * About the safety of MK-1167 and if people tolerate it

Key facts

Study ID

NCT07334860

Run by

Merck Sharp & Dohme LLC

People needed

16

Starts

2026-02-06

Expected to finish

2026-05-20

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤ 32 kg/m\^2, inclusive

You may not qualify if…

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months.

Where it is running

• QPS-MRA, LLC ( Site 0001) — South Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.